- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00992069
Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers
A Phase I, Safety, Tolerability, and Pharmacokinetic Interaction Study of Single-Dose TMC207 and Efavirenz in Healthy Volunteers
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Tuberculosis (TB) is the second most deadly infectious disease after HIV. Multidrug-resistant TB (MDR-TB) has emerged as a worldwide epidemic, limiting treatment options. HIV infected people with suppressed immune systems are particularly susceptible to TB, and TB is the leading cause of death among people with HIV. Treating people infected with both HIV and TB is particularly problematic because rifamycins, the drug class usually used to treat TB, lower the effectiveness of certain anti-HIV medications. Studies of pharmacokinetics (PK), the interactions between drugs and body, are needed to determine which anti-TB and anti-HIV medications can be safely and effectively combined. This study will examine TMC207, a new anti-TB medication with the potential to shorten TB treatment time, combined with efavirenz (EFV), an antiretroviral (ARV) medication used in many first-line treatment regimens for HIV. The study will test PK and safety of this combination in healthy volunteers.
Participation in this study will last 49 days. At entry, participants will complete basic assessments, including taking a medical history and completing a physical exam, an eye exam, an electrocardiogram (ECG) to measure heartbeat, a pregnancy test, and a blood test. Certain behaviors and substances will be prohibited during the study, including consuming grapefruit, alcohol, or caffeine (on PK visit days); taking nutritional supplements, over-the-counter herbal medicines, and certain medicines and drugs from other studies; and excessive smoking. Participants will also be asked to keep a medication diary to record all medications they take during the study.
All participants will receive study medications on the same schedule: a single dose of TMC207 on Days 1 and 29, and daily dosing of EFV on Days 15 to 43.
Participants will complete two PK visits, one from Days 1 to 3, and one from Days 28 to 31. During PK visits, participants will have their vital signs checked and undergo an ECG, and they may also complete a limited physical exam, give a medication history, and report on symptoms. They will have multiple blood samples taken via a catheter left in place for the 3-day visit. Blood samples will be taken before receiving TMC207; 1, 2, 3, 4, 5, 6, 8, and 12 hours after receiving TMC207; and again on the mornings of Days 2 and 3.
Participants will complete six outpatient visits over the 11 days following each PK visit and one outpatient visit on Day 21, between PK visits. At outpatient visits participants will complete a blood draw and may complete a limited physical exam and medical history, record symptoms, and review their medication diaries.
On Day 49 participants will complete their last study visit, repeating many of the assessments from baseline testing. In the case of side effects or abnormal blood tests, participants may be monitored longer for safety reasons.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
California
-
San Francisco, California, Estados Unidos, 94110
- Ucsf Aids Crs
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Johns Hopkins Adult AIDS CRS
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27514
- Unc Aids Crs
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43210
- The Ohio State Univ. AIDS CRS
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232-2582
- Vanderbilt Therapeutics CRS
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Females not of reproductive potential, defined as women who have been postmenopausal for at least 24 consecutive months or women who have undergone hysterectomy, bilateral oophorectomy, or bilateral tubal ligation
- Females who have been surgically sterilized and all males must agree to use contraceptives if participating in sexual activity that could lead to pregnancy while receiving the protocol-specified medications and for 4 weeks after stopping the medication
- Absence of HIV-1 infection, as documented by any licensed enzyme-linked immunosorbent assay (ELISA) test kit, within 21 days prior to study entry
- Estimated creatinine clearance of more than 50 ml/min, within 21 days prior to study entry, calculated by the Cockcroft-Gault method
- Laboratory test results obtained within 21 days prior to entry, including negative pregnancy test, negative hepatitis B and C tests, and certain blood values
Exclusion Criteria:
- Use of any prescription medication known to inhibit or induce CYP3A metabolizing enzymes within 30 days prior to entry
- Planned use during the study, from day 0 through the last PK blood draw, of any of the following: prescription medication(s), herbal supplement(s), nutritional supplement(s), or over-the-counter medication(s). Multivitamins and acetaminophen, up to 650 mg every 6 hours as an analgesic, are permitted.
- Hospitalization for any reason, pharmacotherapy for serious illness, or use of any prescription medication(s) within 14 days prior to study entry
- Receipt of any investigational study drug within 21 days prior to study entry
- Known allergy, sensitivity, or hypersensitivity to EFV or TMC207 or components of their formulations, including cyclodextrin allergy
- Significant previous or active history of cardiovascular, renal, liver, hematologic, neurologic, gastrointestinal, psychiatric, endocrine, or immunologic disease(s), as determined by the site investigator. This is inclusive of chronic illnesses or gastrointestinal conditions that may affect drug absorption, etc. Additionally, any medical condition that, in the opinion of the site investigator, would interfere with the volunteer's ability to participate in the protocol will exclude participation.
- Active illicit drug use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
- Suspicion of active tuberculosis (TB) by the site investigator
- Inability to abstain from alcoholic beverages, grapefruit, and grapefruit juice for the duration of the study
- For smokers, inability to smoke 5 cigarettes per day or less for the duration of the study
- Breastfeeding
- Electrocardiogram (ECG) showing first-degree or greater heart block or QT interval (QTc) greater than 440 ms within 21 days prior to study entry. First-degree heart block is defined as PR interval greater than 200 ms.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: TMC207 alone and with EFV
Participants will receive single-dose TMC207 alone and then single-dose TMC207 with EFV.
|
Oral dose of 600 mg daily, taken in the evening
Outros nomes:
Single oral dose of 400 mg in the morning
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
Area under curve (AUC) over 336 hours of TMC207, measured when dosed alone and when dosed together with efavirenz (EFV) 600 mg daily
Prazo: Measured at baseline and Days 1 to 15, 28, and 29 to 43
|
Measured at baseline and Days 1 to 15, 28, and 29 to 43
|
Signs or symptoms of toxicity ranked Grade 2 or higher, according to the DAIDS adverse event (AE) grading table
Prazo: Throughout study
|
Throughout study
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
---|---|
Maximum observed plasma or serum concentration (Cmax) and oral clearance (CL/F) of TMC207 and AUC, Cmax, and CL/F of the M2 metabolite of TMC207 when dosed alone and when dosed together with EFV 600 mg daily
Prazo: Measured at baseline and Days 1 to 15, 28, and 29 to 43
|
Measured at baseline and Days 1 to 15, 28, and 29 to 43
|
AUC over 24 hours, Cmax, Cmin, CL/F, and elimination half-life (T1/2) of EFV and host EFV metabolism genotype status (CYP2B6) obtained from whole blood samples taken at screening
Prazo: Measured at baseline and on Day 28
|
Measured at baseline and on Day 28
|
Correlation between AUC over 24 hours of EFV and AUC over 336 hours of TMC207
Prazo: Measured at baseline and Days 1 to 15, 28, and 29 to 43
|
Measured at baseline and Days 1 to 15, 28, and 29 to 43
|
Colaboradores e Investigadores
Investigadores
- Cadeira de estudo: Kelly Dooley, MD, Johns Hopkins University
Publicações e links úteis
Publicações Gerais
- Goldman RC, Plumley KV, Laughon BE. The evolution of extensively drug resistant tuberculosis (XDR-TB): history, status and issues for global control. Infect Disord Drug Targets. 2007 Jun;7(2):73-91. doi: 10.2174/187152607781001844.
- McIlleron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis. 2007 Aug 15;196 Suppl 1:S63-75. doi: 10.1086/518655.
- Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, van Heeswijk RP, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, Mc Neeley DF. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009 Jun 4;360(23):2397-405. doi: 10.1056/NEJMoa0808427.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Infecções
- Infecções bacterianas
- Infecções Bacterianas e Micoses
- Infecções por Bactérias Gram-Positivas
- Infecções por Actinomycetales
- Infecções por Mycobacterium
- Tuberculose
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Anti-Infecciosos
- Antivirais
- Inibidores da transcriptase reversa
- Inibidores da Síntese de Ácido Nucleico
- Inibidores Enzimáticos
- Inibidores da enzima citocromo P-450
- Indutores Enzimáticos do Citocromo P-450
- Indutores de citocromo P-450 CYP3A
- Indutores do Citocromo P-450 CYP2B6
- Inibidores do citocromo P-450 CYP2C9
- Inibidores do citocromo P-450 CYP2C19
- Efavirenz
Outros números de identificação do estudo
- A5267
- 10749 (Identificador de registro: DAIDS ES)
- ACTG A5267
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecrutamentoHIV | Teste de HIV | Ligação do HIV ao Cuidado | Tratamento de HIVEstados Unidos
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement e outros colaboradoresDesconhecidoHIV | Crianças não infectadas pelo HIV | Crianças expostas ao HIVCamarões
-
University of MinnesotaRetiradoInfecções por HIV | HIV/AIDS | HIV | AUXILIA | Aids/problema de HIV | AIDS e InfecçõesEstados Unidos
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationConcluídoTeste de HIV do parceiro | Aconselhamento de casal HIV | Comunicação de casal | Incidência de HIVCamarões, República Dominicana, Geórgia, Índia
-
Erasmus Medical CenterAinda não está recrutandoInfecções por HIV | HIV | Infecção por HIV-1 | Infecção HIV IHolanda
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... e outros colaboradoresRecrutamentoHIV | Teste de HIV | Vinculação ao cuidadoÁfrica do Sul
-
National Taiwan UniversityRecrutamento
-
University of Maryland, BaltimoreRetiradoHIV | Transplante de rim | Reservatório de HIV | CCR5Estados Unidos
-
Helios SaludViiV HealthcareDesconhecidoHIV | Infecção por HIV-1Argentina
-
Hospital Clinic of BarcelonaConcluídoInibidores da Integrase, HIV; INIBIDORES DA PROTEASE DO HIVEspanha
Ensaios clínicos em Efavirenz (EFV)
-
Kirby InstituteConcluído
-
Obafemi Awolowo UniversityLondon School of Hygiene and Tropical Medicine; University of California, San... e outros colaboradoresConcluídoInfecção pelo Vírus da Imunodeficiência HumanaNigéria
-
Gilead SciencesConcluído
-
Gilead SciencesConcluídoInfecção por HIV-1Espanha, Estados Unidos, Reino Unido, Suíça, Alemanha, Canadá, França, Bélgica, Porto Rico
-
South East Asia Research Collaboration with HawaiiNational Institute of Neurological Disorders and Stroke (NINDS)ConcluídoInfecção aguda por HIV | Envolvimento do SNC do HIVTailândia
-
French National Agency for Research on AIDS and...Merck Sharp & Dohme LLCConcluído
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...ConcluídoInfecções por HIV | TuberculoseÁfrica do Sul, Zimbábue, Índia, Uganda
-
ANRS, Emerging Infectious DiseasesUniversity of KwaZulu; Africa Centre For Health and Population StudiesConcluídoInfecção pelo HIVÁfrica do Sul
-
All India Institute of Medical Sciences, New DelhiNational AIDS Control OrganisationConcluídoCoinfecção HIV/TBÍndia
-
Janssen-Cilag International NVConcluídoSíndrome da Imunodeficiência Adquirida | Infecção pelo HIV | HIVFrança, Reino Unido, Alemanha, Espanha, Suíça, Israel, Federação Russa, Áustria, Hungria, Romênia, Dinamarca